Viral lymphomas: Can antivirals be used to treat cancer?

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Cesarman, Ethel ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AIDS; EBV; HHV 8; HIV; HTLV 1; KSHV; Lymphoma; Virus

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BORTEZOMIB; DOXORUBICIN; EPSTEIN BARR VIRUS ANTIGEN; GANCICLOVIR; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; STAT PROTEIN; VIRUS PROTEIN; VORINOSTAT; ZIDOVUDINE;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS; LYMPHOMA; LYMPHOMA CELL; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VIRAL LYMPHOMA; VIRUS INFECTION;

ANTIVIRAL AGENTS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LYMPHOMA; VIRAL PROTEINS;

EID: 84859773680     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169155899     Document Type: Article

References (16)

1. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 2006;66:8762-9.
2. Hui KF, Chiang AK. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer. 2010;126:2479-89.
3. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol. 2004;78:1893-902.
4. Iwata S, Saito T, Ito Y, Kamakura M, Gotoh K, Kawada J, et al. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Cancer Sci. 2011;103(2):375-81.
5. Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, et al. Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood. 2011;117:6297-303.
6. Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey NL, Cabral L, et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood. 2005;106:235-40.
7. Kieff E, Rickinson A. Epstein-Barr virus and its replication. In: Fields B, Knipe D, Howley PM, editors. Fields virology. Philadelphia (PA): Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. p. 2603-55.
8. Yin Q, Flemington EK. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology. 2006;346:385-93.
9. Hong M, Murai Y, Kutsuna T, Takahashi H, Nomoto K, Cheng CM, et al. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBVpositive Burkitt's lymphoma cells. J Cancer Res Clin Oncol. 2006;132:1-8.
10. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI, et al. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 2009;5:e1000341.
11. Guasparri I, Bubman D, Cesarman E. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood. 2008;111:3813-20.
12. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 2004;199:993-1003.
13. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30:1379-89.
14. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A. 2006;103:720-5.
15. DiNardo CD, Tsai DE. Treatment advances in posttransplant lymphoproliferative disease. Curr Opin Hematol. 2010;17:368-74.
16. Li N, Thompson S, Schultz DC, Zhu W, Jiang H, Luo C, et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One. 2010;5:e10126.